Common psychosocial factors underlying breast cancer screening and breast cancer treatment adherence: A conceptual review and synthesis

Journal of Women's Health

Volumn 16, Issue 1, 2007, Pages 11-23

  Magai, Carol ^a,c   Consedine, Nathan ^a   Neugut, Alfred I ^b   Hershman, Dawn L ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Intercultural Institute on Human Development and Aging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CANCER SCREENING; CANCER THERAPY; COGNITION; EMOTION; HUMAN; HUMAN RELATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL ASPECT;

BREAST NEOPLASMS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PROFESSIONAL-PATIENT RELATIONS; SOCIAL SUPPORT; UNITED STATES; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 33847226671     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.0024     Document Type: Review

References (164)

1. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. Ann Intern Med 2002;137:305.
2. Burns RB, McCarthy EP, Freund KM, et al. Black women receive less mammography even with similar use of primary care. Ann Intern Med 1996;125:173.
3. Champion VL, Menon U. Predicting mammography and breast self-examination in African American women. Cancer Nurs 1997;20:315.
4. Glanz K, Resch N, Lerman C, Rimer BK. Black-white differences in factors influencing mammography use among employed female health maintenance organization members. Ethnicity Health 1996;1:207.
5. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: A meta-analysis. JAMA 1995;273:149.
6. King ES, Rimer BK, Trock B, Balshem A, Engstrom P. How valid are mammography self-reports? Am J Public Health 1990;80:1386.
7. de Koning HJ. Assessment of nationwide cancer-screening programmes. Lancet 2000;355:80.
8. Benson JR, Pitsinis V. Update on clinical role of tamoxifen. Curr Opin Obstet Gynecol 2003;15:13.
9. Jatoi I, Miller AB. Why is breast-cancer mortality declining? Lancet Oncol 2003;4:251.
10. Green MC, Hortobagyi GN. Adjuvant chemotherapy for breast cancer. Langenbecks Arch Surg 2002;387:109.
11. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:59.
12. Abe O, Abe R, Asaishi K, et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy-133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71.
13. Bergh J, Jonsson P-E, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253.
14. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: Clinical and psychological factors. J Clin Oncol 2004;22:4951.
15. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow-up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005;330:217.
16. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332:901.
17. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281.
18. Hryniuk W, Levine M. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162.
19. Hryniuk W, Frei E III, Wright F. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose intensity. J Clin Oncol 1998;16:3137.
20. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253.
21. Tannock IF, Boyd NG, DeBoer G, et al. A randomized trial of 2 dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377.
22. Consedine NS, Magai C, Neugut AI. The contribution of emotional characteristics to breast cancer screening among women from six ethnic groups. Prev Med 2004;38:64.
23. Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care-A framework for underuse. Med Care 2003;41:442.
24. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003;21:4524.
25. Fisher B, Costantino JP, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989;320:479.
26. Partridge AH, Wang PS, Winer EP, Avorn J. Non-adherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602.
27. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98.
28. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen receptor-negative tumors. N Engl J Med 1998;320:473.
29. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive brjast cancer. J Clin Oncol 2004;22:3309.
30. DiMatteo MR. Variations in patients' adherence to medical recommendations-A quantitative review of 50 years of research. Med Care 2004;42:200.
31. Demissie S, Silliman RA, Lash T. Adjuvant tamoxifen: Predictors of use, side effects and discontinuation in older women. J Clin Oncol 2001;19:322.
32. Mandelblatt JS, Schechter CB, Yabroff KR, et al. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004;22:2554.
33. Jones AL. Reduction in mortality from breast cancer-Screening and increased use of adjuvants are responsible-Adjuvants more so. BMJ 2005;330:205.
34. Magai C, Consedine NS, Conway F, Neugut AI, Culver C. Diversity matters: Unique populations of older women and breast cancer screening. Cancer 2004;100:2300.
35. Suarez L, Ramirez AG, Villarreal R, et al. Social networks and cancer screening in four U.S. Hispanic groups. Am J Prev Med 2000;19:47.
36. Kinney AY, Bloor LE, Martin C, Sandler RS. Social ties and colorectal cancer screening among blacks and whites in North Carolina. Cancer Epidemiol Biomarkers Prev 2005;14:182.
37. Allen JD, Sorensen G, Stoddard AM, Peterson KE, Colditz G. The relationship between social network characteristics and breast cancer screening practices among employed women. Ann Behav Med 1999;21:193.
38. Consedine NS, Magai C, Krivoshekova YS, Ryzewicz L, Neugut AI. Fear, anxiety, worry, and breast cancer screening behavior: A critical review. Cancer Epidemiol Biomarkers Prev 2004;13:501.
39. Andersen MR, Smith R, Meischke H, Bowen D, Urban N. Breast cancer worry and mammography use by women with and without a family history in a population-based sample. Cancer Epidemiol Biomarkers Prev 2003;12:314.
40. Roila F, Ballatori E, Patoia L, et al. Adjuvant systemic therapies in women with breast cancer: An audit of clinical practice in Italy. Ann Oncol 2003;14:843.
41. Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 2003;95:1545.
42. Flaws JA, Bush TL. Racial differences in drug metabolism: An explanation for higher breast cancer mortality in blacks? Med Hypotheses 1998;50:327.
43. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003;8:514.
44. Detmar SB, Muller MJ, Schnornagel JH, Wever LDV, Aaronson NK. Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol 2002;20:1056.
45. Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: A survey of the impact on patient time and activities. BMC Cancer 2004;4:Art No. 20.
46. Ottevanger PB, De Mulder PHM, Grol RPTM, van Lier H, Beex LVAM. Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients. Eur J Cancer 2004;40:198.
47. Andersen BL. Biobehavioral outcomes following psychological interventions for cancer patients. J Consult Clin Psychol 2002;70:590.
48. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: The impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002;17:504.
49. Kaplan RC, Bhalodkar NC, Brown EJ, Wflite J, Brown DL. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications. Prev Med 2004;39:1249.
50. Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med 1998;24:35.
51. Van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care Studies 2002;16:269.
52. Brownbridge G, Fielding DM. Psychosocial adjustment and adherence to dialysis treatment regimens. Pediatr Nephrol 1994;8:744.
53. Kalsekar ID, Madhavan SS, Amonkar MM, et al. Depression in patients with type 2 diabetes: Impact on adherence to oral hypoglycemic agents. Ann Pharmacother 2006;40:605.
54. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment-Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101.
55. Pereira DB, Antoni MH, Danielson A, Simon T, Efantis-Potter J, O'Sullivan MJ. Inhibited interpersonal coping style predicts poorer adherence to scheduled clinic visits in human immunodeficiency virus infected women at risk for cervical cancer. Ann Behav Med 2004;28:195.
56. Cameron LD, Petrie KJ, Ellis CJ, Buick D, Weinman JA. Trait negative affectivity and responses to a health education intervention for myocardial infarction patients. Psychol Health 2005;20:1.
57. DiMatteo MR. Social support and patient adherence to medical treatment: A meta-analysis. Health Psychol 2004;23:207.
58. Lannin DR, Matthews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA 1998;279:1801.
59. Pearlman DN, Rakowski W, Ehrich B, Clark MA. Breast cancer screening practices among black, Hispanic, and white women: Reassessing differences. Am J Prev Med 1996;12:327.
60. Williams DR. The concept of race in health services research. Health Serv Res 1994;29:261.
61. Gil F, Mendez I, Sirgo A, Llort G, Blanco I, Corte-Funes H. Perception of breast cancer risk and surveillance behaviours of women with family history of breast cancer: A brief report on a Spanish cohort. Psycho-Oncology 2003;12:821.
62. Coreil J. Ethnicity and cancer prevention in a tri-ethnic urban community. J Natl Med Assoc 1984;76:1013.
63. Donovan KA, Tucker DC. Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med 2000;2000:15.
64. Hughes C, Gomez-Caminero A, Benkendort J, et al. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Counsel 1997;32:51.
65. Miller AM, Champion V. Attitudes about breast cancer and mammography: Racial, income and educational differences. Women Health 1997;26:41.
66. Valdez A, Banerjee K, Ackerson L, Fernandez M, Otero-Sabogal R, Somkin CP. Correlates of breast cancer screening among low-income, low-education Latinas. Prev Med 2001;33:495.
67. Friedman LC, Moore A, Webb JA, Puryear LJ. Breast cancer screening among ethnically diverse low-income women in a general hospital psychiatry clinic. Gen Hosp Psychiatry 1999;21:374.
68. Lostao L, Joiner TE, Pettit JW, Chorot P, Sandin B. Health beliefs and illness attitudes as predictors of breast cancer screening attendance. Eur J Public Health 2001;11:247.
69. Mandelblatt JS, Gold K, O'Malley AS, et al. Breast and cervix cancer screening among multiethnic women: Role of age, health and source of care. Prev Med 1999;28:418.
70. Powell IJ. Early detection issues of prostate cancer in African American men. In Vivo 1994;8:451.
71. Royak-Schaler R, DeVellis BM, Sorenson JR, Wilson KR, Lannin DR, Emerson JA. Breast cancer in African American families: Risk perception, cancer worry, and screening practices of first-degree relatives. Ann NY Acad Sci 1995;768:281.
72. Tinley ST, Houfek J, Watson P, et al. Screening adherence in BRCA1/2 families is associated with primary physicians' behavior. Am J Med Genet 2004;125A:5.
73. Consedine NS, Magai C, Horton D, Neugut AI, Gillespie M. Health belief model factors in mammography screening: Testing for interactions among subpopulations of Caribbean women. Ethnicity Dis 2005;15:444.
74. Katapodi MC, Lee KA, Facione NC, Dodd MJ. Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: A meta-analytic review. Prev Med 2004;38:388.
75. Husaini BA, Sherkat DE, Bragg R, et al. Predictors of breast cancer screening in a panel study of African American women. Women Health 2001;34:35.
76. Adderley KB, Green PM. Breast cancer education, self-efficacy, and screening in older African American women. J Natl Black Nurses Assoc 1997;9:45.
77. Buelow JR, Zimmer AH, Mellor MJ, Sax R. Mammography screening in older minority women. J Appl Gerontol 1998;17:133.
78. Champion VL, Scott CR. Reliability and validity of breast cancer screening belief scales in African American women. Nurs Res 1997;46:331.
79. Balcazar H, Castro F, Krull J. Cancer risk reduction in Mexican-American women: The role of acculturation, education and health risk factors. Health Educ Q 1995;22:61.
80. Powe BD. Fatalism among elderly African Americans. Cancer Nurs 1995;18:385.
81. Powe BD, Finnie R. Cancer fatalism-The state of the science. Cancer Nurs 2003;26:454.
82. Perez-Stable EJ, Sabogal F, Oteero-Sabogal R, Hiatt RA, McPhee SJ. Misconceptions about cancer among Latinos and Anglos. JAMA 1992;268:3219.
83. Pakentham KI, Pruss M, Clutton S. The utility of socio-demographics, knowledge and health belief model variables in predicting reattendance for mammography screening: A brief report. Psychol Health 2000;15:585.
84. Miller SM, Bowen DJ, Campbell MK, et al. Current research promises and challenges in behavioral oncology: Report from the American Society of Preventive Oncology Annual Meeting, 2002. Cancer Epidemiol Biomarkers Prev 2004;13:171.
85. Bowen DJ, Almut H, Powers D, et al. Predicting breast cancer screening: Intentions and behavior with emotion and cognition. J Soc Clin Psychol 2003;22:213.
86. Cameron LD, Diefenbach MA. Responses to information about psychosocial consequences of genetic testing for breast cancer susceptibility: Influences of cancer worry and risk perceptions. J Health Psychol 2001;6:47.
87. Chapman GB, Coups EJ. Emotions and preventive health behavior: Worry, regret, and influenza vaccination. Health Psychol 2006;25:82.
88. Katapodi MC, Facione NC, Miaskowski C, Dodd MJ, Waters C. The influence of social support on breast cancer screening in a multicultural community sample. Oncol Nurs Forum (Online) 2002;29:845.
89. Taylor VM, Thompson B, Montano DE, Mahloch J, Johnson K, Li S. Mammography use among women attending inner-city clinic. J Cancer Educ 1998;13:96.
90. Tessaro I, Eng E, Smith J. Breast cancer screening in older African American women: Qualitative research findings. Am J Health Promotion 1994;8:286.
91. Consedine NS, Strongman KT, Ma gai C. Emotions and behavior: Data from a cross-cultural recognition study. Cognition Emotion 2003;17:881.
92. Mayne TJ. Negative affect and health: The importance of being earnest. Cognition Emotion 1999;13:601.
93. Consedine NS, Magai C, Bonanno GA. Moderators of the emotion inhibition-health relationship: A review and research agenda. Rev Gen Psychol 2002;6:204.
94. Izard CE. Emotions as motivations: An evolutionary-developmental perspective. 1978. Nebraska Symposium on Motivation, Vol. 26, pg. 163.
95. Izard CE. The psychology of emotions. New York: Plenum Press, 1991.
96. Aro A, de Koning H, Absetz P, Schreck M. Psychosocial predictors of first attendance for organized mammography screening. J Med Screen 1999;6:82.
97. Banks E, Beral V, Cameron R, et al. Comparison of various characteristics of women who do and do not attend breast cancer screening. Breast Cancer Res 2002;4:Art. No. R1.
98. Kerner JF, Yedidia M, Padgett D, et al. Realizing the promise of breast cancer screening: Clinical followup after abnormal screening among black women. Prev Med 2003;37:92.
99. Lindberg NM, Wellisch D. Anxiety and compliance among women at high risk for breast cancer. Ann Behav Med 2001;23:298.
100. Drossaert CHC, Boer H, Seydel ER. Prospective study of the determinants of repeat attending and attendance patterns in breast cancer screening using the theory of planned behavior. Psychol Health 2003;18:551.
101. Sapir R, Patlas M, Strano SD, Hadas-Halpern I, Cherny NI. Does mammography hurt? J Pain Symptom Manage 2003;25:53.
102. Crump SR, Mayberry RM, Taylor BD, Barefield KP, Thomas EP. Factors related to noncompliance with screening mammogram appointments among low-income African American women. J Natl Med Assoc 2000;92:237.
103. de Nooijer J, Lechner L, de Vries H. A qualitative study on detecting cancer symptoms and seeking medical help: An application of Andersen's model of of total patient delay. Patient Educ Counsel 2001;42:145.
104. Garbers S, Jessop DJ, Foti H, Uribelarrea M, Chiasson MA. Barriers to breast cancer screening for low-income Mexican and Dominican women in New York City. J Urban Health: Bull NY Acad Med 2003;80:81.
105. Kee F, Telford AM, Donaghy P, O'Doherty A. Attitude or access: Reasons for not attending mammography in Northern Ireland. Eur J Cancer Prev 1992;1:311.
106. Lerman C, Rimer BK, Trock B, Balshem A, Engstrom PF. Factors associated with repeat adherence to breast cancer screening. Prev Med 1990;19:279.
107. Maxwell AE, Bastani R, Warda US. Breast cancer screening and related attitudes among Filipino-American women. Cancer Epidemiol Biomarkers Prev 1997;6:719
108. Orton M, Fitzpatrick R, Fuller A, Mant D, Mlynek C, Thorogood M. Factors affecting women's response to an invitation to attend for a second breast cancer screening examination. Brit J Gen Pract 1991;41:320.
109. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. Cognitive Ther Res 1992;16:143.
110. Miller SM, Diefenbach MA. The Cognitive-Social Health Information Processing (C-SHIP) model: A theoretical framework for research in behavioral oncology. In: Krantz D, Baum A, eds. Technology and methods in behavioral medicine. Mahwah, NJ: Lawrence Erlbaum, 1998:219.
111. Cameron LD, Leventhal H. Vulnerability beliefs, symptom experiences and the processing of health threat information: A self-regulatory perspective. J Appl Soc Psychol 1995;25:1859.
112. Bener A, Honein G, Carter AO, Da'ar Z, Miller C, Dunn EV. The determinants of breast cancer screening behavior: A focus group study of women in the United Arab Emirates. Oncol Nurs Forum (Online) 2002;29:91.
113. Caplan LS, Helzlsouer KJ, Shapiro S, Wesley MN, Edwards BK. Reasons for delay in breast cancer diagnosis. Prev Med 1996;25:218.
114. Powell DR. Social and psychological aspects of breast cancer in African-American women. Ann NY Acad Sci 1994;736:131.
115. Goldstein DA, Antoni MH. The distribution of repressive coping styles among nonmetastatic and metastatic breast cancer patients and compared to noncancer patients. Psychol Health 1989;3:245.
116. Kreitler S, Chaitchik S, Kreitler H, Weissler K. Who will attend tests for the early detection of breast cancer? Psychol Health 1994;9:463.
117. Kreitler S, Chaitchik S, Kreitler H. The psychological profile of women attending breast-screening tests. Soc Sci Med 1990;31:1177.
118. Hughes C, Lerman C, Lustbader E. Ethnic differences in risk perception among women at increased risk for breast cancer. Breast Cancer Res Treat 1996;40:25.
119. Jessop DC, Rutter DR, Sharma D, Albery IP. Emotion and adherence to treatment in people with asthma: An application of the emotional Stroop paradigm. Br J Psychol 2004;95:127.
120. Ogden J. Some problems with social cognition models: A pragmatic and conceptual analysis. Health Psychol 2003;22:424.
121. Zautra AJ, Davis MC, Smith BW. Emotions, personality, and health: Introduction to the special issue. J Pers 2004;72:1097.
122. Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull 2001;127:267.
123. Mellers BA, McGraw AP. Anticipated emotions as guides to choice. Curr Directions Psychol Sci 2001;10:210.
124. Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE, Jones LW. Exercise motivation and adherence in cancer survivors after participation in a randomized controlled trial: An attribution theory perspective. Int J Behav Med 2004;11:8.
125. Audrain J, Rimer B, Cella D, et al. The impact of a brief coping skills intervention on adherence to breast self-examination among first-degree relatives of newly diagnosed breast cancer patients. Psycho-Oncology 1999;8:220.
126. Seeman TE, Kaplan GA, Knudsen L, Cohen R, Guralnik J. Social network ties and mortality among the elderly in the Alameda County Study. Am J Epidemiol 1987;126:714.
127. Seeman TE, Berkman LF, Kohout F, Lacroix A, Glynn RJ, Blazer DG. Intercommunity variations in the association between social ties and mortality in the elderly: A comparative analysis of three communities. Ann Epidemiol 1993;3:325.
128. House JS, Landis KR, Umberson D. Social relations and health. Science 1998;241:540.
129. Consedine NS, Krivoshekova YS, Harris CR. Bodily embarrassment and judgment concern as separable factors in the measurement of medical embarrassment: Psychometric development and links to treatment-seeking outcomes. Br J Health Psychol 2007;12:1.
130. Lazarus RS. Emotion and adaptation. New York: Oxford University Press, 1991.
131. Levenson RW. Human emotion: A functional view. In: Ekman P, Davidson RJ, eds. The nature of emotion: Fundamental questions. New York: Oxford University Press, 1994:123.
132. Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C, Neugut AI. Prostate cancer screening behavior in men from seven ethnic groups: The fear factor. Cancer Epidemiol Biomarkers Prev 2006;15:228.
133. Mayne TJ. Emotions and health. In: Mayne TJ, Bonanno GA, eds. Emotions: Current issues and future directions. New York: Guilford, 2001:361.
134. Brehm JW, Brummett BH, Harvey L. Paradoxical sadness. Motivation Emotion 1999;23:31.
135. Clark LA, Watson D. Distinguishing functional from dysfunctional affective bursts. In: Ekman P, Davidson RJ, eds. The nature of emotion: Fundamental questions. New York: Oxford University Press, 1994:131.
136. Consedine NS, Magai C. Emotion development in adulthood: A developmental functionalist review and critique. In: Hoare C, ed. The Oxford handbook of adult development and learning. New York: Oxford University Press, 2006:209.
137. Leventhal H, Patrick-Miller L. Emotions and physical illness: Causes and indicators of vulnerability. In: Lewis M, Haviland JM, eds. Handbook of emotions, 2nd ed. New York: Guilford, 2000:523.
138. Waxman MH, McGeary G, Weinrit RM, Carner EA. A comparisons of somatic complaints among depressed and nondepressed older patients. Gerontologist 1987;85:501.
139. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746.
140. Modigliani A. Embarrassment, facework, and eye contact: Testing a theory of embarrassment. J Pers Soc Psychol 1971;17:15.
141. Manstead ASR, Semin GR. Social transgression, social perspectives, and social emotionality. Motivation Emotion 1981;5:249.
142. Miller RS. Embarrassment: Poise and peril in everyday life. New York: Guilford Press, 1996.
143. Keltner D, Anderson C. Saving face for Darwin: The functions and uses of embarrassment. Curr Directions Psychol Sci 2000;9:187.
144. Keltner D, Buswell BN. Evidence for the distinctiveness of embarrassment, shame, and guilt: A study of recalled antecedents and facial expressions of emotion. Cognition Emotion 1996;10:155.
145. Miller RS. The nature and severity of self-reported embarrassing circumstances. Pers Soc Psychol Bull 1992;18:190.
146. Buss AH. Self-consciousness and social anxiety. New York: W. H. Freeman, 1980.
147. Edelmann R. Social embarrassment: An analysis of the process. J Soc Pers Relationships 1985;2:195.
148. Meerabeau L. The management of embarrassment and sexuality in health care. J Adv Nurs 1999;26:1507.
149. Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology 2001;15:613.
150. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640.
151. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485.
152. Grilo CM, Shiftman S, Wing RR. Relapse crises and coping among dieters. J Consult Clin Psychol 1989;57:488.
153. Carmody TP. Affect regulation, nicotine addiction, and smoking cessation. J Psychoactive Drugs 1989;21:331.
154. Cooney ML, Litt MD, Morse PA, Bauer LO. Alcohol cue reactivity, negative mood reactivity, and relapse in treated alcoholic men. J Abnorm Psychol 1997;106:243.
155. Myers LB, Vetere A. Repressors' responses to health-related questionnaires. Br J Health Psychol 1997;2:245.
156. Newton TL, Contrada RJ. Repressive coping and verbal-autonomic response dissociation: The influence of social context. J Pers Soc Psychol 1992;62:159.
157. Myers LB, Reynolds D. How optimistic are repressors? The relationship between repressive coping, controllability, self-esteem and comparative optimism for health-related events. Psychol Health 2000;15:677.
158. Werhun CD, Cox BJ. Levels of anxiety sensitivity in relation to repressive and self-deceptive coping styles. J Anxiety Disord 1999;13:601.
159. Myers LB, Brewin CR. Illusions of well-being and the repressive coping style. Br J Soc Psychol 1996;35:443.
160. Furnham A, Petrides KV, Sisterson G, Baluch B. Repressive coping style and positive self-presentation. Br J Health Psychol 2003;8:223.
161. Diefenbach MA, Miller SM, Daly MB. Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychol 1999;18:532.
162. Magai C, Cohen C, Milburn N, Thorpe B, McPherson R, Peralta D. Attachment styles in older European American and African American adults. J Gerontol [B] Psychol Sci Soc Sci 2001;56B:S28.
163. Magai C. Emotions over the lifespan. In: Birren JE, Schaie KW, eds. Handbook of the psychology of aging, 5th ed. San Diego, CA: Academic Press, 2001:310.
164. Makoni S, Consedine NS, Horton D, Magai C, Kukafka R. Socioeconomic and racial effects in an intervention designed to increase breast screening at six and twelve months: Testing the durability of message impact. Dallas, TX: Gerontological Society of America, 2006.